Algernon Pharmaceuticals (XTER:BTI) EBIT : €-2.48 Mil (TTM As of Feb. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals EBIT?

Algernon Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2024 was €-0.69 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2024 was €-2.48 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Algernon Pharmaceuticals's annualized ROC % for the quarter that ended in Feb. 2024 was -105.76%. Algernon Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Algernon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -137.70%.

Algernon Pharmaceuticals EBIT Historical Data

The historical data trend for Algernon Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals EBIT Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

EBIT

Get a 7-Day Free Trial

-1.30

-5.53

-5.43

-4.60

-3.57

Algernon Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EBIT	Get a 7-Day Free Trial															-0.87	-0.77	-0.67	-0.35	-0.69

Competitive Comparison of Algernon Pharmaceuticals's EBIT

For the Biotechnology subindustry, Algernon Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algernon Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's EV-to-EBIT falls into.

Algernon Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.48 Mil.

Algernon Pharmaceuticals (XTER:BTI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Algernon Pharmaceuticals's annualized ROC % for the quarter that ended in Feb. 2024 is calculated as:

	ROC % (Q: Feb. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Nov. 2023 )	+	Invested Capital (Q: Feb. 2024 ))	/ count )
=	-2.756 * ( 1 - 0% )	/	( (2.581	+	2.631)	/ 2 )
=	-2.756	/	2.606
=	-105.76 %

where

	Invested Capital		(Q: Nov. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.663	-	1.981	-	( 0.05	-	max(0, 1.981	-	0.082	+	0.05	))
=	2.581

	Invested Capital		(Q: Feb. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.715	-	2.415	-	( 0.052	-	max(0, 2.415	-	0.084	+	0.052	))
=	2.631

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Algernon Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Feb. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Nov. 2023		Q: Feb. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.756	/	( ( (0 + max(-1.958, 0))	+	(0 + max(-2.404, 0)) )	/	2 )
=	-2.756	/	( ( 0	+	0 )	/	2 )
=	-2.756	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Nov. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.023)	-	(1.981	+	0	+	0)
=	-1.958

	Working Capital		(Q: Feb. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.011)	-	(2.415	+	0	+	0)
=	-2.404

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Algernon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Feb. 2024 )
	=	-2.48	/	1.801
	=	-137.70 %

Algernon Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (XTER:BTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XTER:BTI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.